The right place for IL-1 inhibition in COVID-19
Authors:
- 1 March 2021
- journal article
- editorial
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 9 (3) , 223-224
Abstract
No abstract availableFunding Information
- Ministero della Salute
- Foundation for Research in Rheumatology
- Associazione Italiana per la Ricerca sul Cancro
This publication has 8 references indexed in Scilit:
- Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 DiabetesCell Metabolism, 2021
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 PneumoniaJAMA Internal Medicine, 2021
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyEuropean Journal of Internal Medicine, 2020
- Anakinra for severe forms of COVID-19: a cohort studyThe Lancet Rheumatology, 2020
- Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort studyThe Lancet Rheumatology, 2020
- Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumoniaCritical Care, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammationProceedings of the National Academy of Sciences, 2018